These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12069125)

  • 41. DNA cancer vaccines: a gene gun approach.
    Mahvi DM; Sheehy MJ; Yang NS
    Immunol Cell Biol; 1997 Oct; 75(5):456-60. PubMed ID: 9429892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prodrugs in genetic chemoradiotherapy.
    Patterson AV; Saunders MP; Greco O
    Curr Pharm Des; 2003; 9(26):2131-54. PubMed ID: 14529410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retrovirus-mediated gene transfer in cancer therapy.
    Uckert W; Walther W
    Pharmacol Ther; 1994 Sep; 63(3):323-47. PubMed ID: 7530375
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma.
    Fakhrai H; Mantil JC; Liu L; Nicholson GL; Murphy-Satter CS; Ruppert J; Shawler DL
    Cancer Gene Ther; 2006 Dec; 13(12):1052-60. PubMed ID: 16826191
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oligonucleotide therapeutics: a step forward.
    Gewirtz AM
    J Clin Oncol; 2000 May; 18(9):1809-11. PubMed ID: 10784620
    [No Abstract]   [Full Text] [Related]  

  • 46. Current strategies in cancer gene therapy.
    El-Aneed A
    Eur J Pharmacol; 2004 Sep; 498(1-3):1-8. PubMed ID: 15363969
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The significance of specific oligonucleotides in clinical medicine and their use in the treatment of patients with infective diseases].
    Bojić I
    Vojnosanit Pregl; 1996; 53(5):399-408. PubMed ID: 9229959
    [No Abstract]   [Full Text] [Related]  

  • 48. Antisense therapeutics in oncology: points to consider in their clinical evaluation.
    Mani S; Gu Y; Wadler S; Fingert H
    Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):543-7. PubMed ID: 10645781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel approaches to the treatment of small-cell lung cancer.
    Zangemeister-Wittke U; Stahel RA
    Cell Mol Life Sci; 1999 Sep; 55(12):1585-98. PubMed ID: 10526576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cancer vaccines.
    Pardoll DM
    Immunol Today; 1993 Jun; 14(6):310-6. PubMed ID: 8397772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of gene therapy in cancer research and treatment.
    Shinohara ET; Lu B; Hallahan DE
    Technol Cancer Res Treat; 2004 Oct; 3(5):479-90. PubMed ID: 15453813
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modification of alternative splicing pathways as a potential approach to chemotherapy.
    Mercatante D; Kole R
    Pharmacol Ther; 2000 Mar; 85(3):237-43. PubMed ID: 10739878
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Approaches to gene-directed enzyme prodrug therapy (GDEPT).
    Springer CJ; Niculescu-Duvaz I
    Adv Exp Med Biol; 2000; 465():403-9. PubMed ID: 10810644
    [No Abstract]   [Full Text] [Related]  

  • 54. Antisense oligonucleotides to p53 tumor suppressor suppress the induction of apoptosis by epidermal growth factor in NCI-H 596 human lung cancer cells.
    Murayama Y; Horiuchi S
    Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):109-14. PubMed ID: 9149846
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.
    Nishi Y
    Curr Pharm Des; 2003; 9(26):2113-30. PubMed ID: 14529409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The systemic treatment of advanced cutaneous melanoma.
    Logan TF
    Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290
    [No Abstract]   [Full Text] [Related]  

  • 57. 10 years and counting: the hype and hope of cancer biotechnology.
    Morris K
    Lancet Oncol; 2002 Oct; 3(10):582. PubMed ID: 12372706
    [No Abstract]   [Full Text] [Related]  

  • 58. [Do dendritic cells modified with retroviral vectors carrying cytokine genes become a therapeutic tool?].
    Szyda A; Rossowska J; Pajtasz-Piasecka E; Duś D
    Postepy Hig Med Dosw (Online); 2006; 60():552-62. PubMed ID: 17115005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective gene therapy for proliferative disorders: sense and antisense.
    Indolfi C; Chiariello M; Avvedimento EV
    Nat Med; 1996 Jun; 2(6):634-5. PubMed ID: 8640548
    [No Abstract]   [Full Text] [Related]  

  • 60. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.
    Xu M; Lu X; Kallinteris NL; Wang Y; Wu S; von Hofe E; Gulfo JV; Humphreys RE; Hillman GG
    Curr Opin Mol Ther; 2004 Apr; 6(2):160-5. PubMed ID: 15195928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.